APO Research
Talk to an analyst

APO RESEARCH · REPORT

Leiomyosarcoma Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Leiomyosarcoma Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025183 pages

Choose your research edition.

Industry ResearchLeiomyosarcoma Drug Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Leiomyosarcoma Drug Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Leiomyosarcoma Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Leiomyosarcoma Drug Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Leiomyosarcoma Drug Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Leiomyosarcoma Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Leiomyosarcoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Leiomyosarcoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Leiomyosarcoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Leiomyosarcoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Leiomyosarcoma Drug include Novartis AG, Merck & Co., Inc., Vicore Pharma AB, Mirati Therapeutics Inc., Karyopharm Therapeutics, Inc., Cell Medica Limited, BeiGene, Ltd. and Advenchen Laboratories, LLC, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Leiomyosarcoma Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Leiomyosarcoma Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Leiomyosarcoma Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Leiomyosarcoma Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Leiomyosarcoma Drug Segment by Company

Novartis AG

Merck & Co., Inc.

Vicore Pharma AB

Mirati Therapeutics Inc.

Karyopharm Therapeutics, Inc.

Cell Medica Limited

BeiGene, Ltd.

Advenchen Laboratories, LLC

Leiomyosarcoma Drug Segment by Type

BGB-290

C-21

AL-3818

Others

Leiomyosarcoma Drug Segment by Application

Clinic

Hospital

Others

Leiomyosarcoma Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Leiomyosarcoma Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Leiomyosarcoma Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Leiomyosarcoma Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Leiomyosarcoma Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Leiomyosarcoma Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Leiomyosarcoma Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Leiomyosarcoma Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Leiomyosarcoma Drug Industry Trends Table 2. Leiomyosarcoma Drug Industry Drivers Table 3. Leiomyosarcoma Drug Industry Opportunities and Challenges Table 4. Leiomyosarcoma Drug Industry Restraints Table 5. Global Leiomyosarcoma Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Leiomyosarcoma Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Leiomyosarcoma Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Leiomyosarcoma Drug Sales Market Share by Manufacturers Table 9. Global Leiomyosarcoma Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Leiomyosarcoma Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Leiomyosarcoma Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Leiomyosarcoma Drug Manufacturers, Product Type & Application Table 13. Global Leiomyosarcoma Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Leiomyosarcoma Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of BGB-290 Table 17. Major Manufacturers of C-21 Table 18. Major Manufacturers of AL-3818 Table 19. Major Manufacturers of Others Table 20. Global Leiomyosarcoma Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Leiomyosarcoma Drug Sales by Type (2021-2026) & (K Units) Table 22. Global Leiomyosarcoma Drug Sales by Type (2027-2032) & (K Units) Table 23. Global Leiomyosarcoma Drug Sales Market Share by Type (2021-2026) Table 24. Global Leiomyosarcoma Drug Sales Market Share by Type (2027-2032) Table 25. Global Leiomyosarcoma Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Leiomyosarcoma Drug Revenue by Type (2021-2026) & (K Units) Table 27. Global Leiomyosarcoma Drug Revenue by Type (2027-2032) & (K Units) Table 28. Global Leiomyosarcoma Drug Revenue Market Share by Type (2021-2026) Table 29. Global Leiomyosarcoma Drug Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Clinic Table 31. Major Manufacturers of Hospital Table 32. Major Manufacturers of Others Table 33. Global Leiomyosarcoma Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Leiomyosarcoma Drug Sales by Application (2021-2026) & (K Units) Table 35. Global Leiomyosarcoma Drug Sales by Application (2027-2032) & (K Units) Table 36. Global Leiomyosarcoma Drug Sales Market Share by Application (2021-2026) Table 37. Global Leiomyosarcoma Drug Sales Market Share by Application (2027-2032) Table 38. Global Leiomyosarcoma Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Leiomyosarcoma Drug Revenue by Application (2021-2026) & (K Units) Table 40. Global Leiomyosarcoma Drug Revenue by Application (2027-2032) & (K Units) Table 41. Global Leiomyosarcoma Drug Revenue Market Share by Application (2021-2026) Table 42. Global Leiomyosarcoma Drug Revenue Market Share by Application (2027-2032) Table 43. Global Leiomyosarcoma Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Leiomyosarcoma Drug Sales by Region (2021-2026) & (K Units) Table 45. Global Leiomyosarcoma Drug Sales Market Share by Region (2021-2026) Table 46. Global Leiomyosarcoma Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Leiomyosarcoma Drug Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Leiomyosarcoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Leiomyosarcoma Drug Sales by Country (2021-2026) & (K Units) Table 50. North America Leiomyosarcoma Drug Sales by Country (2027-2032) & (K Units) Table 51. Europe Leiomyosarcoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Leiomyosarcoma Drug Sales by Country (2021-2026) & (K Units) Table 53. Europe Leiomyosarcoma Drug Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Leiomyosarcoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Leiomyosarcoma Drug Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Leiomyosarcoma Drug Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Leiomyosarcoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Leiomyosarcoma Drug Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Leiomyosarcoma Drug Sales by Country (2027-2032) & (K Units) Table 60. Global Leiomyosarcoma Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Leiomyosarcoma Drug Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Leiomyosarcoma Drug Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Leiomyosarcoma Drug Revenue Market Share by Region (2021-2026) Table 64. Global Leiomyosarcoma Drug Revenue Market Share by Region (2027-2032) Table 65. Novartis AG Company Information Table 66. Novartis AG Business Overview Table 67. Novartis AG Leiomyosarcoma Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Novartis AG Leiomyosarcoma Drug Product Portfolio Table 69. Novartis AG Recent Development Table 70. Merck & Co., Inc. Company Information Table 71. Merck & Co., Inc. Business Overview Table 72. Merck & Co., Inc. Leiomyosarcoma Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Merck & Co., Inc. Leiomyosarcoma Drug Product Portfolio Table 74. Merck & Co., Inc. Recent Development Table 75. Vicore Pharma AB Company Information Table 76. Vicore Pharma AB Business Overview Table 77. Vicore Pharma AB Leiomyosarcoma Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Vicore Pharma AB Leiomyosarcoma Drug Product Portfolio Table 79. Vicore Pharma AB Recent Development Table 80. Mirati Therapeutics Inc. Company Information Table 81. Mirati Therapeutics Inc. Business Overview Table 82. Mirati Therapeutics Inc. Leiomyosarcoma Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Mirati Therapeutics Inc. Leiomyosarcoma Drug Product Portfolio Table 84. Mirati Therapeutics Inc. Recent Development Table 85. Karyopharm Therapeutics, Inc. Company Information Table 86. Karyopharm Therapeutics, Inc. Business Overview Table 87. Karyopharm Therapeutics, Inc. Leiomyosarcoma Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Karyopharm Therapeutics, Inc. Leiomyosarcoma Drug Product Portfolio Table 89. Karyopharm Therapeutics, Inc. Recent Development Table 90. Cell Medica Limited Company Information Table 91. Cell Medica Limited Business Overview Table 92. Cell Medica Limited Leiomyosarcoma Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Cell Medica Limited Leiomyosarcoma Drug Product Portfolio Table 94. Cell Medica Limited Recent Development Table 95. BeiGene, Ltd. Company Information Table 96. BeiGene, Ltd. Business Overview Table 97. BeiGene, Ltd. Leiomyosarcoma Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. BeiGene, Ltd. Leiomyosarcoma Drug Product Portfolio Table 99. BeiGene, Ltd. Recent Development Table 100. Advenchen Laboratories, LLC Company Information Table 101. Advenchen Laboratories, LLC Business Overview Table 102. Advenchen Laboratories, LLC Leiomyosarcoma Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Advenchen Laboratories, LLC Leiomyosarcoma Drug Product Portfolio Table 104. Advenchen Laboratories, LLC Recent Development Table 105. Key Raw Materials Table 106. Raw Materials Key Suppliers Table 107. Leiomyosarcoma Drug Distributors List Table 108. Leiomyosarcoma Drug Customers List Table 109. Research Programs/Design for This Report Table 110. Authors List of This Report Table 111. Secondary Sources Table 112. Primary Sources List of Figures Figure 1. Leiomyosarcoma Drug Product Image Figure 2. Global Leiomyosarcoma Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Leiomyosarcoma Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Leiomyosarcoma Drug Sales (2021-2032) & (K Units) Figure 5. Global Leiomyosarcoma Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Leiomyosarcoma Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. BGB-290 Image Figure 9. C-21 Image Figure 10. AL-3818 Image Figure 11. Others Image Figure 12. Global Leiomyosarcoma Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Leiomyosarcoma Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Leiomyosarcoma Drug Sales Market Share by Type (2021-2032) Figure 15. Global Leiomyosarcoma Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Leiomyosarcoma Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Leiomyosarcoma Drug Revenue Market Share by Type (2021-2032) Figure 18. Clinic Image Figure 19. Hospital Image Figure 20. Others Image Figure 21. Global Leiomyosarcoma Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Leiomyosarcoma Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Leiomyosarcoma Drug Sales Market Share by Application (2021-2032) Figure 24. Global Leiomyosarcoma Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Leiomyosarcoma Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Leiomyosarcoma Drug Revenue Market Share by Application (2021-2032) Figure 27. North America Leiomyosarcoma Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Leiomyosarcoma Drug Sales Market Share by Country (2021-2032) Figure 29. U.S. Leiomyosarcoma Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Leiomyosarcoma Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Leiomyosarcoma Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Leiomyosarcoma Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Leiomyosarcoma Drug Sales Market Share by Country (2021-2032) Figure 34. Germany Leiomyosarcoma Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Leiomyosarcoma Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Leiomyosarcoma Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Leiomyosarcoma Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Leiomyosarcoma Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Leiomyosarcoma Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Leiomyosarcoma Drug Sales Market Share by Country (2021-2032) Figure 41. China Leiomyosarcoma Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Leiomyosarcoma Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Leiomyosarcoma Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Leiomyosarcoma Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Leiomyosarcoma Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Leiomyosarcoma Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Leiomyosarcoma Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Leiomyosarcoma Drug Sales Market Share by Country (2021-2032) Figure 49. Brazil Leiomyosarcoma Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Leiomyosarcoma Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Leiomyosarcoma Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Leiomyosarcoma Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Leiomyosarcoma Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Leiomyosarcoma Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Leiomyosarcoma Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Leiomyosarcoma Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Leiomyosarcoma Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Leiomyosarcoma Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Leiomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Figure 60. North America Leiomyosarcoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Leiomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Figure 62. Europe Leiomyosarcoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Leiomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Leiomyosarcoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Leiomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Leiomyosarcoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Leiomyosarcoma Drug Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Leiomyosarcoma Drug Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • BGB-290
  • C-21
  • AL-3818
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Novartis AG
  • Merck & Co., Inc.
  • Vicore Pharma AB
  • Mirati Therapeutics Inc.
  • Karyopharm Therapeutics, Inc.
  • Cell Medica Limited
  • BeiGene, Ltd.
  • Advenchen Laboratories, LLC

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Leiomyosarcoma Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Leiomyosarcoma Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Leiomyosarcoma Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Leiomyosarcoma Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Leiomyosarcoma Drug Market Dynamics
  1. 2.1 Leiomyosarcoma Drug Industry Trends
  2. 2.2 Leiomyosarcoma Drug Industry Drivers
  3. 2.3 Leiomyosarcoma Drug Industry Opportunities and Challenges
  4. 2.4 Leiomyosarcoma Drug Industry Restraints
3 Leiomyosarcoma Drug Market by Manufacturers
  1. 3.1 Global Leiomyosarcoma Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Leiomyosarcoma Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Leiomyosarcoma Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Leiomyosarcoma Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Leiomyosarcoma Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Leiomyosarcoma Drug Manufacturers, Product Type & Application
  7. 3.7 Global Leiomyosarcoma Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Leiomyosarcoma Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Leiomyosarcoma Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Leiomyosarcoma Drug Tier 1, Tier 2, and Tier 3
4 Leiomyosarcoma Drug Market by Type
  1. 4.1 Leiomyosarcoma Drug Type Introduction
  2. 4.1.1 BGB-290
  3. 4.1.2 C-21
  4. 4.1.3 AL-3818
  5. 4.1.4 Others
  6. 4.2 Global Leiomyosarcoma Drug Sales by Type
  7. 4.2.1 Global Leiomyosarcoma Drug Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Leiomyosarcoma Drug Sales by Type (2021-2032)
  9. 4.2.3 Global Leiomyosarcoma Drug Sales Market Share by Type (2021-2032)
  10. 4.3 Global Leiomyosarcoma Drug Revenue by Type
  11. 4.3.1 Global Leiomyosarcoma Drug Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Leiomyosarcoma Drug Revenue by Type (2021-2032)
  13. 4.3.3 Global Leiomyosarcoma Drug Revenue Market Share by Type (2021-2032)
5 Leiomyosarcoma Drug Market by Application
  1. 5.1 Leiomyosarcoma Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Leiomyosarcoma Drug Sales by Application
  6. 5.2.1 Global Leiomyosarcoma Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Leiomyosarcoma Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Leiomyosarcoma Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Leiomyosarcoma Drug Revenue by Application
  10. 5.3.1 Global Leiomyosarcoma Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Leiomyosarcoma Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Leiomyosarcoma Drug Revenue Market Share by Application (2021-2032)
6 Global Leiomyosarcoma Drug Sales by Region
  1. 6.1 Global Leiomyosarcoma Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Leiomyosarcoma Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Leiomyosarcoma Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Leiomyosarcoma Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Leiomyosarcoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Leiomyosarcoma Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Leiomyosarcoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Leiomyosarcoma Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Leiomyosarcoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Leiomyosarcoma Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Leiomyosarcoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Leiomyosarcoma Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Leiomyosarcoma Drug Revenue by Region
  1. 7.1 Global Leiomyosarcoma Drug Revenue by Region
  2. 7.1.1 Global Leiomyosarcoma Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Leiomyosarcoma Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Leiomyosarcoma Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Leiomyosarcoma Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Leiomyosarcoma Drug Revenue (2021-2032)
  8. 7.2.2 North America Leiomyosarcoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Leiomyosarcoma Drug Revenue (2021-2032)
  11. 7.3.2 Europe Leiomyosarcoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Leiomyosarcoma Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Leiomyosarcoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Leiomyosarcoma Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Leiomyosarcoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Leiomyosarcoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Leiomyosarcoma Drug Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 Merck & Co., Inc.
  8. 8.2.1 Merck & Co., Inc. Company Information
  9. 8.2.2 Merck & Co., Inc. Business Overview
  10. 8.2.3 Merck & Co., Inc. Leiomyosarcoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck & Co., Inc. Leiomyosarcoma Drug Product Portfolio
  12. 8.2.5 Merck & Co., Inc. Recent Developments
  13. 8.3 Vicore Pharma AB
  14. 8.3.1 Vicore Pharma AB Company Information
  15. 8.3.2 Vicore Pharma AB Business Overview
  16. 8.3.3 Vicore Pharma AB Leiomyosarcoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Vicore Pharma AB Leiomyosarcoma Drug Product Portfolio
  18. 8.3.5 Vicore Pharma AB Recent Developments
  19. 8.4 Mirati Therapeutics Inc.
  20. 8.4.1 Mirati Therapeutics Inc. Company Information
  21. 8.4.2 Mirati Therapeutics Inc. Business Overview
  22. 8.4.3 Mirati Therapeutics Inc. Leiomyosarcoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Mirati Therapeutics Inc. Leiomyosarcoma Drug Product Portfolio
  24. 8.4.5 Mirati Therapeutics Inc. Recent Developments
  25. 8.5 Karyopharm Therapeutics, Inc.
  26. 8.5.1 Karyopharm Therapeutics, Inc. Company Information
  27. 8.5.2 Karyopharm Therapeutics, Inc. Business Overview
  28. 8.5.3 Karyopharm Therapeutics, Inc. Leiomyosarcoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Karyopharm Therapeutics, Inc. Leiomyosarcoma Drug Product Portfolio
  30. 8.5.5 Karyopharm Therapeutics, Inc. Recent Developments
  31. 8.6 Cell Medica Limited
  32. 8.6.1 Cell Medica Limited Company Information
  33. 8.6.2 Cell Medica Limited Business Overview
  34. 8.6.3 Cell Medica Limited Leiomyosarcoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Cell Medica Limited Leiomyosarcoma Drug Product Portfolio
  36. 8.6.5 Cell Medica Limited Recent Developments
  37. 8.7 BeiGene, Ltd.
  38. 8.7.1 BeiGene, Ltd. Company Information
  39. 8.7.2 BeiGene, Ltd. Business Overview
  40. 8.7.3 BeiGene, Ltd. Leiomyosarcoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 BeiGene, Ltd. Leiomyosarcoma Drug Product Portfolio
  42. 8.7.5 BeiGene, Ltd. Recent Developments
  43. 8.8 Advenchen Laboratories, LLC
  44. 8.8.1 Advenchen Laboratories, LLC Company Information
  45. 8.8.2 Advenchen Laboratories, LLC Business Overview
  46. 8.8.3 Advenchen Laboratories, LLC Leiomyosarcoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Advenchen Laboratories, LLC Leiomyosarcoma Drug Product Portfolio
  48. 8.8.5 Advenchen Laboratories, LLC Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Leiomyosarcoma Drug Value Chain Analysis
  2. 9.1.1 Leiomyosarcoma Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Leiomyosarcoma Drug Production Mode & Process
  6. 9.2 Leiomyosarcoma Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Leiomyosarcoma Drug Distributors
  9. 9.2.3 Leiomyosarcoma Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst